News

26/02/2025 Enodia Therapeutics

Argobio and the Institut Pasteur launch Enodia Therapeutics: A biotech company with a new approach for Targeted protein Degradation

Turning groundbreaking research from the Institut Pasteur with the support of Argobio’s start-up studio, into novel treatments for cancer, inflammatory diseases and viral infections.   The platform leverages state-of-the-art generative artificial intelligence (AI) to design selective inhibitors of the Sec61/translocon molecular complex for blocking and degrading...

Learn more

07/01/2025 Inverna

Next-generation RNA company Inverna Therapeutics launched by Argobio and University of Southern Denmark

Denmark  Odense  07/01/2025 – Inverna Therapeutics, a novel Danish biotech company at the forefront of innovative RNA therapeutics, today announced its launch as a leading-edge RNA therapeutics company.  The Company was co-founded by the University of Southern Denmark and Argobio and is dedicated to transforming patient outcomes in severe genetic diseases, starting...

Learn more

20/09/2024 Temper Bio

Argobio Portfolio Company Temper Bio Wins i-Lab Innovation Award for Groundbreaking Work in Chronic Inflammatory Disease Treatments

Temper Bio is revolutionizing the treatment of chronic inflammatory diseases with a novel approach based on the neurokine TAFA4. The company is extending this breakthrough therapy to address neuro-inflammation, an emerging therapeutic field with high unmet medical needs.     Paris, France, September 20th, 2024 – Temper Bio, a biotechnology...

Learn more

25/09/2023 Crucible Therapeutics

Northern Gritstone and Argobio Studio back Sheffield University spin-out Crucible Therapeutics

Crucible Therapeutics develops novel therapies treating neurological diseases with significant unmet medical needs, Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal dementia (FTD).   Paris, France, Manchester and Sheffield, United-Kingdom, September 21st, 2023 - Crucible Therapeutics, a biotechnology company developing novel therapies to treat amyotrophic lateral...

Learn more

02/08/2022 Laigo Bio

Oncode Institute and ArgoBio launch Laigo Bio, a targeted protein degradation biotech with programs in oncology and neurological disorders

  www.laigobio.com   A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders.   Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February...

Learn more

16/12/2021 Kevad Bio

Argobio and GeneCode Partner on Parkinson’s Disease in Argobio’s First Announced Research Agreement

A collaboration to develop a new class of small molecule for the treatment of Parkinson's disease and other indications.   Argobio will fund the development of this innovative project up to €3 million and incorporate a new specialized biotechnology company.   With €50M in capital, Argobio and its team of experienced entrepreneurs-in-residence...

Learn more

02/03/2021 ARGOBIO

Argobio announces its launch with 50 M€ to create and develop pioneering biotech spinouts with the support of Bpifrance, Kurma Partners, Angelini Pharma, Evotec, and the Institut Pasteur

Argobio is a French start-up studio aiming at creating at least five ambitious therapeutic biotech spinouts over the next five years   Argobio has 50 M€ of share capital committed by a syndicate of complementary and strategic investors with a shared goal to develop some of Europe’s most promising biotech innovations   Argobio will incubate early-stage,...

Learn more